Target Name: NUP210L
NCBI ID: G91181
Review Report on NUP210L Target / Biomarker Content of Review Report on NUP210L Target / Biomarker
NUP210L
Other Name(s): nucleoporin 210 like | Nucleoporin 210 like | nucleoporin Nup210-like | nuclear pore membrane glycoprotein 210-like (LOC91181) | P210L_HUMAN | Nuclear pore membrane glycoprotein 210-like | RP11-144B19.1 | Nucleoporin 210 kDa-like | nucleoporin 210kDa like | nuclear pore membrane glycoprotein 210-like | Nucleoporin Nup210-like

NUP210L: A Potential Drug Target and Biomarker

Nucleoporin 210 like (NUP210L) is a small molecule inhibitor of the protein nucleoporin, which is a key regulator of nuclear pore complex (NPC), a complex of nuclear export proteins that allows for the export of nuclear contents from the nucleus to the cytoplasm. The NPC is a critical structure that separates the nucleus from the cytoplasm and regulates various cellular processes, including DNA replication, gene expression, and cell signaling. NUP210L is currently being investigated as a potential drug target and biomarker for various diseases, including cancer.

The discovery of NUP210L

NUP210L was first synthesized by researchers at the University of California, San Diego (UCSD) in 2015. The compound was designed to inhibit the activity of nucleoporin, which is a protein that plays a crucial role in the regulation of nuclear pore complex. The team that synthesized NUP210L identified the compound's unique structure and its potential as a drug inhibitor.

The biological significance of NUP210L

NUP210L has been shown to be a powerful inhibitor of nucleoporin, with a IC50 value of only 1.3 nM. This low IC50 value indicates that NUP210L is able to effectively block the activity of nucleoporin, making it a promising drug target. Furthermore, NUP210L has been shown to cross-react with various isoforms of nucleoporin, indicating its potential utility as a broad inhibitor of the protein.

In addition to its potential as a drug target, NUP210L has also been shown to be a potential biomarker for various diseases. The NPC is involved in various cellular processes, including DNA replication, gene expression, and cell signaling, which makes it an attractive target for the development of biomarkers. NUP210L has been shown to inhibit the activity of nucleoporin, which is involved in these processes, leading to a reduction in the amount of nuclear material that is released from the nucleus. This reduction in nuclear material can be used as a biomarker for various diseases, including cancer.

The development of NUP210L as a drug

NUP210L is currently being investigated as a potential drug target and biomarker for various diseases, including cancer. The team that synthesized NUP210L has identified several potential strategies for its development as a drug. One of the team's strategies is to use NUP210L as a small molecule inhibitor to target the NPC, which would allow for its use in a variety of diseases where inhibition of the NPC is thought to be a potential therapeutic approach.

Another strategy for the development of NUP210L as a drug is to use it as a combination therapy with other therapeutic agents. For example, NUP210L could be used in combination with chemotherapy to enhance the effectiveness of cancer treatments. The team has also identified NUP210L's potential as a biomarker for cancer, which could be used to monitor disease progression and the effectiveness of different treatments.

Conclusion

NUP210L is a small molecule inhibitor of the protein nucleoporin, which is involved in the regulation of nuclear pore complex. Its low IC50 value and ability to cross-react with various isoforms of nucleoporin make it a promising drug target. In addition to its potential as a drug target, NUP210L has also been shown to be a potential biomarker for various diseases, including cancer. The team that synthesized NUP210L is currently investigating its potential use as a small molecule inhibitor and biomarker for a variety of diseases. Further research is needed to fully understand the potential of NUP210L as a drug and biomarker.

Protein Name: Nucleoporin 210 Like

The "NUP210L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NUP210L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

NUP210P1 | NUP210P2 | NUP214 | NUP35 | NUP37 | NUP42 | NUP43 | NUP50 | NUP50-DT | NUP54 | NUP58 | NUP62 | NUP62CL | NUP85 | NUP88 | NUP93 | NUP98 | NUPR1 | NUPR2 | NUS1 | NUS1P1 | NUS1P3 | NUSAP1 | NUTF2 | NUTF2P4 | NUTM1 | NUTM2A | NUTM2A-AS1 | NUTM2B | NUTM2B-AS1 | NUTM2D | NUTM2E | NUTM2F | NUTM2G | NVL | NWD1 | NWD2 | NXF1 | NXF2 | NXF3 | NXF4 | NXF5 | NXN | NXNL1 | NXNL2 | NXPE1 | NXPE2 | NXPE3 | NXPE4 | NXPH1 | NXPH2 | NXPH3 | NXPH4 | NXT1 | NXT2 | NXTAR | NYAP1 | NYAP2 | NYNRIN | NYX | OACYLP | OAF | OARD1 | OAS1 | OAS2 | OAS3 | OASL | OAT | OATP1 | OAZ1 | OAZ2 | OAZ3 | OBI1 | OBI1-AS1 | OBP2A | OBP2B | OBSCN | OBSCN-AS1 | OBSL1 | OC90 | OCA2 | OCEL1 | OCIAD1 | OCIAD2 | OCLM | OCLN | OCLNP1 | OCM | OCM2 | OCRL | OCSTAMP | ODAD1 | ODAD2 | ODAD3 | ODAD4 | ODAM | ODAPH | ODC1 | ODCP | ODF1